Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells

Journal of Urology

Volumn 184, Issue 6, 2010, Pages 2557-2564

  Hwang, Jung Jin ^a   Kim, Yong Sook ^a   Kim, Mi Joung ^a   Kim, Dong Eun ^a   Jeong, In Gab ^b   Kim, Choung Soo ^c  

^a Institute for Innovative Cancer Research   (South Korea)

^b Asan Medical Center   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

Author keywords

Apoptosis; Docetaxel; Histone deacetylases; Prostate; Prostatic neoplasms

Indexed keywords

BELINOSTAT; BIK PROTEIN; BIM PROTEIN; CASPASE 3; CASPASE 8; CASPASE 9; DOCETAXEL; HISTONE DEACETYLASE INHIBITOR; PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; PROTEIN MCL 1; TUBULIN; UNCLASSIFIED DRUG; VORINOSTAT;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL STRAIN LNCAP; CYTOTOXICITY; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; DRUG SYNERGISM; HISTONE DEACETYLASE INHIBITORS; HUMANS; MALE; MICE; MICE, INBRED BALB C; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TAXOIDS; TUBULIN; TUMOR CELLS, CULTURED;

EID: 78349309562     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.07.035     Document Type: Article

References (30)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2009 CA Cancer J Clin 59 2009 225
2. D.P. Petrylak, C.M. Tangen, and M.H. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513
3. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502
4. M.D. Galsky, and N.J. Vogelzang Docetaxel-based combination therapy for castration-resistant prostate cancer Ann Oncol 2010 Epub ahead of print
5. R.W. Johnstone, and J.D. Licht Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4 2003 13
6. M.R. Acharya, A. Sparreboom, and J. Venitz Rational development of histone deacetylase inhibitors as anticancer agents: a review Mol Pharmacol 68 2005 917
7. S. Minucci, and P.G. Pelicci Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer Nat Rev Cancer 6 2006 38
8. W.S. Xu, R.B. Parmigiani, and P.A. Marks Histone deacetylase inhibitors: molecular mechanisms of action Oncogene 26 2007 5541
9. K.B. Glaser HDAC inhibitors: clinical update and mechanism-based potential Biochem Pharmacol 74 2007 659
10. A. Mai, S. Massa, and D. Rotili Histone deacetylation in epigenetics: an attractive target for anticancer therapy Med Res Rev 25 2005 261
11. A. Abbas, and S. Gupta The role of histone deacetylases in prostate cancer Epigenetics 3 2008 300
12. A. Insinga, S. Monestiroli, and S. Ronzoni Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway Nat Med 11 2005 71
13. S.J. Haggarty, K.M. Koeller, and J.C. Wong Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation Proc Natl Acad Sci U S A 100 2003 4389
14. P. Bali, M. Pranpat, and J. Bradner Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors J Biol Chem 280 2005 26729
15. C. Subramanian, A.W. Opipari Jr, and X. Bian Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors Proc Natl Acad Sci U S A 102 2005 4842
16. P. Thelen, S. Schweyer, and B. Hemmerlein Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells Int J Oncol 24 2004 25
17. D.Z. Qian, Y.F. Wei, and X. Wang Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models Prostate 67 2007 1182
18. X. Qian, G. Ara, and E. Mills Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer Int J Cancer 122 2008 1400
19. C.W. D'Acunto, B. Fontanella, and M. Rodriquez Histone deacetylase inhibitor FR235222 sensitizes human prostate adenocarcinoma cells to apoptosis through up-regulation of Annexin A1 Cancer Lett 295 2010 85
20. D. Rathkopf, B.Y. Wong, and R.W. Ross A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer Cancer Chemother Pharmacol 66 2010 181
21. G. Daugaard, K. Fizazi, and G. Huebner An open-label randomized phase II trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) compared to carboplatin and paclitaxel in patients with previously untreated carcinoma of unknown primary J Clin Oncol 28 suppl. 2010 15s abstract TPS185
22. T. Reid, S. Thorne, and F. Hedjran Impact of the histone deacetylase inhibitors on taxotere resistance due to P-gp (MDR) and tubulin acetylation Proc Amer Assoc Cancer Res 46 2005
23. L. Di Croce, M. Buschbeck, and A. Gutierrez Altered epigenetic signals in human disease Cancer Biol Ther 3 2004 831
24. G. Di Lorenzo, W.D. Figg, and S.D. Fossa Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study Eur Urol 54 2008 1089
25. M.S. Kim, M. Blake, and J.H. Baek Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA Cancer Res 63 2003 7291
26. Y. Chen, C.L. Sawyers, and H.I. Scher Targeting the androgen receptor pathway in prostate cancer Curr Opin Pharmacol 8 2008 440
27. G. Piperno, M. LeDizet, and X.J. Chang Microtubules containing acetylated alpha-tubulin in mammalian cells in culture J Cell Biol 104 1987 289
28. Z. Zhang, J. Stanfield, and E. Frenkel Enhanced therapeutic effect on androgen-independent prostate cancer by depsipeptide (FK228), a histone deacetylase inhibitor, in combination with docetaxel Urology 70 2007 396
29. M. Kanzaki, H. Kakinuma, and T. Kumazawa Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the effects of gemcitabine and docetaxel in hormone refractory prostate cancer cells Oncol Rep 17 2007 761
30. B.J. Schneider, D. Bradley, and D.C. Smith Phase I study of vorinostat plus docetaxel in patients with solid tumor malignancies J Clin Oncol, suppl. 27 2009 15s abstract 2528